Septest Limited secures £1.1m to advance rapid infection diagnostic tools

Developing rapid diagnostic tools to combat antimicrobial resistance is the core focus of Septest Limited, which has just secured an estimated £1.1m in new funding. The Potters Bar-based company specialises in the creation of TRISEP, a multi-marker blood test intended for the early detection of infections and inflammation.

The TRISEP tool is designed for use by healthcare professionals across community, emergency, and acute care environments. By providing faster diagnostic results, the company aims to improve patient outcomes. The technology is intended to assist in the identification of inflammatory responses and infections within these specific clinical settings.

This funding round values the business at an estimated £4.5m post-money. Documentation for the share allotment was filed in May 2026, following the issuance of new shares.

Founded in 2022, Septest Limited operates within the medical technology sector, focusing on the manufacture of diagnostic instruments and supplies. Latest financial filings indicate the company currently has one employee. This capital injection follows the company's activity since its incorporation four years prior to the filing. No specific lead investors were named in the recent filings.